News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biomedical Advanced Research and Development Authority (BARDA) Exercises Contract Option as Emergent BioSolutions (EBS) Achieves Significant Progress in rPA Anthrax


10/5/2012 9:43:44 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions (NYSE:EBS) announced today that, after completion of an inter-agency In Process Review, the Biomedical Advanced Research Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) has exercised a contract option to further advance the development of PreviThraxTM (Recombinant Protective Antigen Anthrax Vaccine, Purified), the company’s novel rPA anthrax vaccine candidate. This option is part of the company’s rPA development contract with BARDA executed in October 2010.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES